HC Wainwright Analysts Lift Earnings Estimates for DNLI

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.68) per share for the quarter, up from their previous estimate of ($0.69). HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($2.39) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $2.15 EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the previous year, the company posted ($0.68) earnings per share.

Other equities analysts have also issued reports about the company. Wedbush reduced their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective on the stock. B. Riley reiterated a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Bank of America reduced their price target on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Stock Down 1.4%

Shares of Denali Therapeutics stock traded down $0.19 during trading on Monday, hitting $13.97. 134,021 shares of the stock traded hands, compared to its average volume of 1,091,593. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -5.05 and a beta of 1.49. The firm's fifty day moving average is $14.13 and its 200-day moving average is $19.74. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in shares of Denali Therapeutics by 0.3% in the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock worth $3,880,000 after buying an additional 497 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after buying an additional 885 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its position in shares of Denali Therapeutics by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock worth $548,000 after buying an additional 1,058 shares during the last quarter. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after buying an additional 1,551 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.